ASCCP Releases Innovative ‘Enduring Guidelines’ to Combat Cervical Cancer

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CLARKSBURG, MD / ACCESSWIRE / March 7, 2024 / The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud to announce a major milestone by the groundbreaking Enduring Guidelines initiative, aimed at revolutionizing the fight against cervical cancer.

In a bid to ensure the most current and effective clinical management strategies, the Enduring Guidelines process seeks to integrate emerging technologies and the latest scientific evidence into the management of this preventable disease. Cervical cancer, which is preventable through vaccination against human papillomavirus, screening and clinical management of abnormal results, remains a significant global health challenge. To address this, ASCCP, the American Cancer Society (ACS), the National Cancer Institute (NCI) and several other organizations initiated the Enduring Guidelines project following the establishment of the 2019 ASCCP Consensus Guidelines for Clinical Management – the first risk-based guidelines for cervical cancer.

The Enduring Guidelines effort ensures timely updates to the guidelines, incorporating rapidly emerging technologies and new scientific evidence. Two key papers mark significant milestones in this ongoing effort:

  • Nicolas Wentzensen, MD, PhD, MS, Division of Cancer Epidemiology and Genetics, National Cancer Institute: Outlines the Enduring Guidelines approach and methods, demonstrating a commitment to staying at the forefront of cervical cancer prevention and management.
  • Megan A. Clarke, PhD, MHS, Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute: Presents the first clinical recommendations from the Enduring Guidelines group on the use of dual stain cytology to manage abnormal cervical screening results. These recommendations offer invaluable insights into enhancing patient care and outcomes.

“The Enduring Guidelines initiative marks a significant step forward in our ongoing battle against cervical cancer,” says President of ASCCP, Dr. Levi S. Downs, Jr. MD, MS. “By continuously updating our clinical management strategies based on the latest evidence and technologies, we are better equipped to save lives and reduce the burden of this disease.”

ASCCP encourages healthcare professionals, researchers, and stakeholders to explore the Enduring Guidelines and join the collective effort to eradicate cervical cancer. For more information about the initiative and to access the latest clinical recommendations, visit ASCCP’s Enduring Guidelines page.

Furthermore, ASCCP invites individuals to explore the esteemed lineup of speakers at the 2024 ASCCP Scientific Meeting being held in New Orleans, May 2-4, which includes a session on “Enduring Guidelines: What’s Next” with Dr. Wentzensen. To view the speakers and their contributions, visit ASCCP’s 2024 Speakers page.

The American Society for Colposcopy and Cervical Pathology (ASCCP) is dedicated to improving the health of women through the delivery of high-quality, evidence-based care. ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. For media inquiries or interviews, please contact: info@asccp.org

Contact Information
Robert Pulley
Membership Manager
info@asccp.org
301.857.7877

SOURCE: The American Society for Colposcopy and Cervical Pathology

View the original press release on newswire.com.

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

17 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

17 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

17 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

17 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

17 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

17 hours ago